Analysts Pile In as RCUS Bounces from Last Week's Lows

Arcus Biosciences has recovered sharply from the $22.51 trough of a week ago, and the rebound has arrived alongside a wave of analyst activity that is both unusual in its volume and uniform in its direction.

The stock closed Tuesday at $23.75, up 7.3% on the day and 5.5% on the week. Among its closest correlated peers, the median weekly gain was 3.6%, so Arcus outpaced the group. IRON was the standout in that cohort, up 40% on the week, while CADL slipped 6.8%. The broader peer picture was therefore mixed, making Arcus's recovery look more stock-specific than a sector-wide move.

Three target raises arrived on Wednesday alone, all maintaining positive ratings. Citigroup's analyst lifted the target to $50 from $45, the most aggressive call in the group. Wedbush moved to $49 from $43. Truist Securities went to $41 from $40. William Blair initiated with Outperform earlier in the week. JP Morgan, which launched coverage last Tuesday with Overweight and a $41 target, is now one of a crowd. The consensus price target has risen to $40.85, implying roughly 72% upside from Tuesday's close. That gap between price and target has been a persistent feature of this stock, but the direction of travel on targets is now clearly upward. Wells Fargo remains the lone holdout on the bullish pile, keeping an Equal-Weight rating with a $26 target.

The bull argument turns on casdatifan, Arcus's HIF-2α inhibitor targeting clear cell renal cell carcinoma. KOL feedback has been positive about differentiation from belzutifan, with 80%-plus non-rebounding EPO suppression cited as a meaningful clinical distinction. The upcoming ARC-20 readout, covering 121 monotherapy patients and roughly 45 treated with casdatifan plus cabozantinib, is the near-term catalyst the Street is pricing toward. Peak worldwide revenue estimates for casdatifan in ccRCC have been raised to $3.2 billion. The bear case rests on execution risk: the Q2 net loss was $91 million, and while the company carries $775 million in cash expected to last into at least the second half of 2028, there is no commercial revenue to anchor the valuation. Anemia, hypoxia, and treatment discontinuation rates remain a tolerability overhang that could limit adoption even if trial data hold up.

Short positioning is worth noting but does not dominate the story here. Short interest is running at approximately 10.9% of the free float, about 13.5 million shares, up around 1.3% on the week. That is a meaningful level for a clinical-stage biotech, and shorts have been adding gradually over the past month. But the borrow market is far from tight: availability is at 762%, meaning there are roughly seven shares available to borrow for every one already borrowed. Cost to borrow has eased over the week to 0.39%, a multi-month low for the series. The lending setup is not consistent with aggressive short conviction; it looks more like a structural hedge than a directional pile-on.

The options picture is more charged. The put/call ratio jumped to 0.48 on Tuesday, more than 2.4 standard deviations above its 20-day average of 0.18. That is among the highest readings of the past year, with the 52-week high at 0.71. The context matters: through early October, the PCR was running as low as 0.09 to 0.10, suggesting call-heavy positioning. The shift in the past two sessions represents a genuine re-pricing of downside protection ahead of earnings, which are scheduled for November 3.

Gilead Sciences holds 24.7% of the company under a Schedule 13D filing, making it an activist-registered 13D holder on the ORTEX EDGAR register. The stake has edged down from 25.6% at the prior filing in August. BlackRock added approximately 1.2 million shares in the most recent quarter to hold 12.9% of shares, and FMR added close to 2.9 million shares to reach 3.2%. Those additions from large passive and active managers represent genuine buying against a backdrop of insider activity that has tilted the other way: the President sold roughly 2 million dollars of stock across several tranches in June and July, all under pre-arranged 10b5-1 plans. Pre-arranged sales carry less signal than discretionary selling, but the pattern is worth keeping in view.

What changes the picture is the ARC-20 readout and the November 3 earnings print. Wikipedia attention for Arcus, a rough gauge of retail interest, ran at a z-score of almost 4.0 relative to the prior 90 days, measured in late September, so outside attention has been elevated. The next data point that either confirms or dents the casdatifan differentiation story will determine whether the gap between $23.75 and the analyst consensus of $40.85 starts to close or widens further.